TD Asset Management’s Passage Bio PASG Stock Holding History

TD Asset Management’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-525	Closed	-$287K	–	1386
2020 Q2	$287K	Hold	525	–	–	﹤0.01%	1270
2020 Q1	$165K	Buy	+525	New	+$164K	﹤0.01%	1324

Other funds holding PASG

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TD Asset Management's PASG Position: Q3 2020 in Review

TD Asset Management sold out of Passage Bio (PASG) in Q3 2020, closing a stake of 525 shares — an estimated $287K sold.

TD Asset Management first reported a position in PASG in Q1 2020 and held it in 2 quarters. The position peaked at $287K in Q2 2020. 70 funds tracked by Wall St. Rank hold PASG as of Q3 2020.

TD Asset Management reported no remaining Passage Bio position as of Q3 2020 after selling out during the quarter.
TD Asset Management sold 525 Passage Bio shares in Q3 2020, an estimated $287K.
TD Asset Management first reported a position in Passage Bio in Q1 2020 and held it in 2 quarters.
TD Asset Management's Passage Bio position peaked at $287K in Q2 2020.
70 funds tracked by Wall St. Rank held Passage Bio as of Q3 2020.

Based on TD Asset Management's 13F filing for Q3 2020, filed 10 Nov 2020.